Table 6.

Multivariable Cox Regression Model on Time to First Atherosclerotic Event Using Intention‐to‐Treat Analysis

Variable	Hazard Ratio (95% CI)	P Value
Treatment (cinacalcet/placebo)	0.88 (0.76 to 1.01)	0.066
Age	1.03 (1.02 to 1.03)	<0.001
Sex (ref, female)	1.17 (1.01 to 1.36)	0.039
History of transient ischemic attack	1.43 (1.10 to 1.87)	0.008
History of coronary artery disease	1.58 (1.30 to 1.91)	<0.001
History of cardiac arrhythmia	1.36 (1.12 to 1.67)	0.002
History of diabetes	1.76 (1.47 to 2.10)	<0.001
History of bone fracture	1.11 (0.94 to 1.31)	0.224
History of peripheral vascular disease	1.69 (1.43 to 2.00)	<0.001
History of retinopathy	1.27 (1.07 to 1.51)	0.007
History of revascularization	1.37 (1.12 to 1.67)	0.002
Tobacco use (ref, never)		<0.001
Current	1.50 (1.23 to 1.82)
Former	1.14 (0.97 to 1.34)
Baseline aspirin use	1.05 (0.90 to 1.23)	0.543
Baseline amiodarone use	0.79 (0.53 to 1.19)	0.260
Baseline proton pump inhibitor use	1.08 (0.93 to 1.25)	0.333
Baseline warfarin use	1.03 (0.78 to 1.34)	0.854
Bone‐specific alkaline phosphatase, ng/L	0.99 (0.98 to 1.01)	0.222
N‐telopeptide (log‐transformed)	1.09 (0.98 to 1.21)	0.131
Baseline serum albumin, g/dL	0.66 (0.54 to 0.82)	<0.001
Systolic blood pressure per 10 mm Hg increase	1.06 (1.02 to 1.09)	0.001

Variables were selected by backward elimination. The baseline variables calcium‐containing phosphate binder use, corrected serum calcium, cholesterol, serum phosphorus, calcium phosphorus product, high‐density lipoprotein and low‐density lipoprotein cholesterol were not included in the regression model due to lack of statistically significant independent association with the end point at α=0.25 in a separate model for each. Baseline use of aspirin, amiodarone, proton pump inhibitor, or warfarin was added to the final model. P=0.11 for interaction of treatment with age. P value for difference between treatment assignment effect on atherosclerotic and nonatherosclerotic end points=0.622.